The role of mTOR in depression and antidepressant responses
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941 · cited 1×
“The mTOR pathway is dysregulated in human diseases, such as diabetes, obesity, depression, and certain cancers (Beevers et al., 2006; Cornu et al., 2013; Zoncu et al., 2011).”
BackgroundAntidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889 · cited 2×
“Other symptoms may also occur, including loss (or increase) in appetite, insomnia (or excessive sleep), fatigue, feelings of worthlessness and guilt, difficulty concentrating, and recurrent thoughts about death, among others (Krishnan and Nestler, 2008).”
BackgroundmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 8×
“Thus, further characterization of these actions of NMDA receptor blockade and signaling pathways that stimulate mTOR signaling andmediate the rapid induction of synapses in the hippocampus, amygdala, prefrontal cortex and striatum will provide novel therapeutic targets for antidepressant drug development (Li et al., 2…”
BackgroundInfluentialSarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
New approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589 · cited 1×
“Although therapy for depression with drugs, psychotherapy and electroconvulsive therapy are effective, a significant number of patients do not respond well to these treatments (Anderson, 1996; Berton and Nestler, 2006).”
BackgroundPeterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A., Kuehl, W. M., Gray, N. S., & Sabatini, D. M. (2009) · Cell · doi:10.1016/j.cell.2009.03.046 · Cited by 1,202
The Descriptive Epidemiology of Commonly Occurring Mental Disorders in the United States
Kessler, R. C., & Wang, P. S. (2008) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.29.020907.090847 · Cited by 888 · cited 1×
“The mental disorder known as major depression is the most common mood disorder, affecting 5% of the population every year (Kessler and Wang, 2008; Lopez and Mathers, 2006).”
BackgroundSignaling pathways underlying the rapid antidepressant actions of ketamine
Duman, R. S., Li, N., Liu, R.-J., Duric, V., & Aghajanian, G. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.044 · Cited by 537 · cited 2×
“Mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates the initiation of protein translation, and is expressed in dendritic development that controls new protein synthesis (Duman et al., 2012).”
Background
Cited by
The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders
Réus, G. Z., Fries, G. R., Stertz, L., Badawy, M., Passos, I. C., Barichello, T., Kapczinski, F., & Quevedo, J. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.018 · Cited by 594
Self-citationPerluigi, M., Di Domenico, F., & Butterfield, D. A. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.03.014 · Cited by 339
Impact of COVID-19 in the Mental Health in Elderly: Psychological and Biological Updates
Grolli, R. E., Mingoti, M. E. D., Bertollo, A. G., Luzardo, A. R., Quevedo, J., Réus, G. Z., & Ignácio, Z. M. (2021) · Molecular Neurobiology · doi:10.1007/s12035-020-02249-x · Cited by 258
Self-citationHibicke, M., Landry, A. N., Kramer, H. M., Talman, Z. K., & Nichols, C. D. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00493 · Cited by 205
Tolahunase, M. R., Sagar, R., Faiq, M., & Dada, R. (2018) · Restorative Neurology and Neuroscience · doi:10.3233/rnn-170810 · Cited by 167
Giacobbe, J., Benoiton, B., Zunszain, P., Pariante, C. M., & Borsini, A. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00122 · Cited by 159
Creatine for the Treatment of Depression
Kious, B. M., Kondo, D. G., & Renshaw, P. F. (2019) · Biomolecules · doi:10.3390/biom9090406 · Cited by 74
“These intracellular signals have been implicated in the pathogenesis of depression [35,36], potentially because of their effects on synaptic sprouting, mediated by BDNF [37].”
Liang, G., Kow, A. S. F., Yusof, R., Tham, C. L., Ho, Y.-C., & Lee, M. T. (2024) · Biomedicines · doi:10.3390/biomedicines12010184 · Cited by 68
“The activation of mTORC1 has several outcomes, including increased synaptic formation, enhanced neural plasticity, and rapid antidepressant effects [66,67].”
BackgroundZinc, future mono/adjunctive therapy for depression: Mechanisms of antidepressant action
Nowak, G. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2015.01.015 · Cited by 65
Isoflurane produces antidepressant effects inducing BDNF-TrkB signaling in CUMS mice
Zhang, S.-S., Tian, Y.-H., Jin, S.-J., Wang, W.-C., Zhao, J.-X., Si, X.-M., Zhang, L., Xu, H., & Jin, J.-Y. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05287-z · Cited by 49
Dattilo, V., Amato, R., Perrotti, N., & Gennarelli, M. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00826 · Cited by 49
Llorens-Martín, M., Jurado-Arjona, J., Bolós, M., Pallas-Bazarra, N., & Ávila, J. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.12.019 · Cited by 43
“However, increasing evidence suggests that MD is related to distinct peripheral and central pro-inflammatory mechanisms (Abelaira et al., 2014; Ceretta et al., 2012; Dantzer et al., 2008; Hoyo-Becerra et al., 2014; Iseme et al., 2014; Menard et al., 2015; Schiepers et al., 2005).”
miRNAs in depression vulnerability and resilience: novel targets for preventive strategies
Lopizzo, N., Zonca, V., Cattane, N., Pariante, C. M., & Cattaneo, A. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-02048-2 · Cited by 37
O’Brien, B., Lijffijt, M., Wells, A., Swann, A. C., & Mathew, S. J. (2019) · Pharmaceuticals · doi:10.3390/ph12030133 · Cited by 33
“Ketamine’s antidepressant effect has been related to pre- and post-synaptic NMDAR blockade, enhancing prefrontal [10] and hippocampal [11] glutamate concentrations which activate the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR), enhancing synaptic plasticity via AMPAR-induced elevation of brai…”
BackgroundHow do serotonergic psychedelics treat depression: The potential role of neuroplasticity
Artin, H., Zisook, S., & Ramanathan, D. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i6.201 · Cited by 33
Metadata
- Authors
- Abelaira, H. M., Réus, G. Z., Neotti, M. V., & Quevedo, J.
- Venue
- Life Sciences
- Publisher
- Elsevier BV
- Published
- 2014-04
- Volume
- 101
- Issue
- 1-2
- Pages
- 10-14
- ISSN
- 0024-3205 (ISSN-L)
- OpenAlex
- W2024451767
- Cited by
- 186
- References
- 16
- FWCI
- 9.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.